Characterization of MET Alterations in 37 Gastroesophageal Cancer Cell Lines for MET-Targeted Therapy
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25115975 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Jin-Soo Kim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul 07061, Republic of Korea. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-met, Stomach Neoplasms, Triazines, Xenograft Model Antitumor Assays. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Boramae Medical Center.
Abstract (Originalsprache)
Capmatinib and savolitinib, selective MET inhibitors, are widely used to treat various MET-positive cancers. In this study, we aimed to determine the effects of these inhibitors on MET-amplified gastric cancer (GC) cells. Methods: After screening 37 GC cell lines, the following cell lines were found to be MET-positive with copy number variation >10: SNU-620, ESO51, MKN-45, SNU-5, and OE33 cell lines. Next, we assessed the cytotoxic response of these cell lines to capmatinib or savolitinib alone using cell counting kit-8 and clonogenic cell survival assays. Western blotting was performed to assess the effects of capmatinib and savolitinib on the MET signaling pathway. Xenograft studies were performed to evaluate the in vivo therapeutic efficacy of savolitinib in MKN-45 cells. Savolitinib and capmatinib exerted anti-proliferative effects on MET-amplified GC cell lines in a dose-dependent manner. Savolitinib inhibited the phosphorylation of MET and downstream signaling pathways, such as the protein kinase B (AKT) and extracellular signal-regulated kinase (ERK) pathways, in MET-amplified GC cells. Additionally, savolitinib significantly decreased the number of colonies formed on the soft agar and exerted dose-dependent anti-tumor effects in an MKN-45 GC cell xenograft model. Furthermore, a combination of trastuzumab and capmatinib exhibited enhanced inhibition of AKT and ERK activation in human epidermal growth factor receptor-2 (HER2)- and MET-positive OE33 cells. Targeting MET with savolitinib and capmatinib efficiently suppressed the growth of MET-amplified GC cells. Moreover, these MET inhibitors exerted synergistic effects with trastuzumab on HER2- and MET-amplified GC cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul 07061, Republic of Korea.
- College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea.
Förderung
- Boramae Medical Center
Zitieren
APA
Kim, J. S., Kim, M. Y., & Hong, S. (2024). Characterization of MET Alterations in 37 Gastroesophageal Cancer Cell Lines for MET-Targeted Therapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25115975
Vancouver
Kim JS, Kim MY, Hong S. Characterization of MET Alterations in 37 Gastroesophageal Cancer Cell Lines for MET-Targeted Therapy. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25115975
BibTeX
@article{Kim2024,
author = {Kim, Jin-Soo and Kim, Mi Young and Hong, Sungyoul},
title = {Characterization of MET Alterations in 37 Gastroesophageal Cancer Cell Lines for MET-Targeted Therapy},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25115975}
}
EUVIMED